Pituitary Gland Adenoma
NCI Definition: A non-metastasizing tumor that arises from the adenohypophysial cells of the anterior lobe of the pituitary gland. The tumor can be hormonally functioning or not. The diagnosis can be based on imaging studies and/or radioimmunoassays. Due to its location in the sella turcica, expansion of the tumor mass can impinge on the optic chiasm or involve the temporal lobe, third ventricle and posterior fossa A frequently associated physical finding is bitemporal hemianopsia which may progress to further visual loss. 
Pituitary gland adenomas most frequently harbor alterations in PRKDC, KMT2D, FANCA, BRCA2, and ARID1B .
PRKDC Mutation, KMT2D Mutation, FANCA Mutation, BRCA2 Mutation, and ARID1B Mutation are the most common alterations in pituitary gland adenoma .
There is 1 clinical trial for pituitary gland adenoma, of which 1 is open and 0 are completed or closed. Of the trial that contains pituitary gland adenoma as an inclusion criterion, 1 is phase 2 (1 open).
Ipilimumab and nivolumab are the most common interventions in pituitary gland adenoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.